Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05560646 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain
A Phase 2 study, sponsored by Organon and.
- Completed
- Registry status
- Phase 2
- Development phase
- 354
- Enrollment target
NCT05560646: Completed Phase 2 study, sponsored by Organon and.
NCT05560646 is a Phase 2 study that has completed, run by Organon and. The registered enrollment target is 354 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (166% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05560646, a Phase 2 study, has completed, sponsored by Organon and.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 354 participants
- Enrollment target
Study Summary
The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.
Primary Outcome
Participants completed eDiary items for severity of their pain over the last 24 hours on 11-point NRS for dysmenorrhea or NMPP, and dyspareunia. Each item of the NRS pain severity score ranged from 0 (no pain) to 10 (worst pain imaginable), where lower score indicated a better outcome. The mean OPP score was derived by the pain score for the dysmenorrhea and NMPP items, and score ranged from 0 (no pain) to 10 (worst pain imaginable), where lower score indicated a better outcome. Baseline cycle O
Interventions
- DRUG Placebo
- DRUG OG-6219
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 354 participants |
| Start Date | 2022-10-25 |
| Est. Completion | 2025-05-28 |
| Phase | Phase 2 |
What the finished NCT05560646 record still lists
NCT05560646 is an interventional study that assigns participants to a tested intervention. The registered 354 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (166% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05560646 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05560646 about?
NCT05560646 is a clinical study titled "A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain". The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.
What is the current status of trial NCT05560646?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 354 participants. The study started on 2022-10-25. Estimated completion is 2025-05-28.
What interventions are being tested in trial NCT05560646?
The interventions under investigation include: Placebo (DRUG), OG-6219 (DRUG).
Who is sponsoring clinical trial NCT05560646?
This trial is sponsored by Organon and, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05560646's enrollment target sits among peer trials
354 128th of 2000 higher than 1,872 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02579967 · 354 participants · Phase 2
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
- NCT02610413 · 354 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
- NCT05729256 · 354 participants · NA
Alcohol and "Heat of the Moment" Sexual Decision Making
- NCT06507618 · 354 participants · Phase 3
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI